CA
PRME icon

Clearstead Advisors’s Prime Medicine PRME Stock Holding History

Clearstead Advisors’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34 Buy
+9
New +$30 ﹤0.01% 3533

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
ACM
Alessandra Capital Management Torrance, California $141M AUM
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Clearstead Advisors's PRME Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Prime Medicine (PRME) in Q2 2026: 9 shares worth $34. The stake represents ﹤0.01% of the portfolio and ranks #3533 among its holdings.

67 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Clearstead Advisors held 9 shares of Prime Medicine worth $34 as of Q2 2026.
  • Prime Medicine was a new Clearstead Advisors position in Q2 2026.
  • Prime Medicine made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3533 holding.
  • 67 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.